Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657857 | 0.86 | MAOB (0.38) | MAOBCYP2A6ACHERAB9AMAOA | |
| SCHEMBL5668839 | 0.71 | KIF11 (0.34) | MAOBMAOA | |
| SCHEMBL4098698 | 0.71 | STK17B (0.38) | MAOBCYP1A2ACHEMAOA | |
| SCHEMBL5658380 | 0.69 | NPC1 (0.43) | MAOBCYP2A6CYP1A2ACHECYP19A1 | |
| SCHEMBL27847892 | 0.68 | CYP1A2 (0.76) | CYP2A6CYP1A2CYP11B1CYP11B2CYP2C9 | |
| SCHEMBL5657363 | 0.68 | KDM4E (0.41) | MAOBCYP2A6CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL5414434 | 0.68 | CYP11B1 (0.37) | CYP2A6CYP1A2CYP11B1CYP11B2ACHE | |
| SCHEMBL5251983 | 0.67 | CYP2A6 (0.56) | MAOBCYP2A6CYP1A2RAB9ANPC1 | |
| SCHEMBL806603 | 0.65 | TRPA1 (0.48) | MAOBCYP2A6CYP1A2ACHECYP19A1 | |
| SCHEMBL21165169 | 0.64 | CYP2A6 (0.41) | MAOBCYP2A6CYP1A2ACHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262309-B2 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) | 2007-08-28 | — | — | US | disclosed |
| EP-1492795-B1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2005-11-16 | — | — | EP | disclosed |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.D.D. (HR) | 2005-06-23 | — | — | US | disclosed |
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | MAOB 2392/4885CYP2A6 639/4885CYP1A2 408/4885 |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | MAOB 1806/4885CYP2A6 393/4885CYP1A2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.